Medication info

Glarinduol Tablet 2.5/1000 Milligrams

Prescription medicationTabletOralExpired
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Eden Pharma Co., Ltd.
Appearance
Bright pink, biconvex, oval film-coated tablet
Packaging
60 tablets/box [(10 tablets/PTP packaging x 6)]
Approval status
Expired

MFDS item code 202001539 · Approved 2020.03.05

This product's status changed to Expired on 2025.03.05. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medication should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of the individual components: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medication is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior history of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, the initial dose is 1 tablet of this medication 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medication 2.5/1000 mg twice daily. 2. Patients who do not achieve adequate glycemic control with metformin monotherapy: The initial dose of this medication should provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medication should start at their current doses of linagliptin and metformin. 4. Patients who do not achieve adequate glycemic control with combination therapy with metformin and a sulfonylurea: The initial dose of this medication should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medication is administered concomitantly with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Administer with caution to the following patients). 5. Patients who do not achieve adequate glycemic control with combination therapy with insulin and metformin: The initial dose of this medication should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medication is administered concomitantly with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Administer with caution to the following patients). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral hypoglycemic agents to this medication. Any change in treatment for type 2 diabetes may cause a change in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, provided the dose is adjusted as follows. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 1. Do not administer to the following patients).

Ingredients

Manufacturer
Eden Pharma Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Difficulty in controlling blood sugar in patients with type 2 diabetes
View approved original text

This medication is used alongside dietary and exercise therapy to help control blood sugar in adult patients with type 2 diabetes. It may be administered to those who have no prior experience with diabetes medication treatment or who find it difficult to control blood sugar with monotherapy. Additionally, it is used when monotherapy with Metformin is insufficient and can replace the combination therapy of Linagliptin and Metformin. In cases where blood sugar control is inadequate with Metformin in combination with sulfonylurea or insulin, this drug can be co-administered to enhance efficacy. If blood sugar remains uncontrolled even after combination therapy with empagliflozin and Metformin, this drug can be added for treatment. In summary, this medication is used to improve blood sugar control in various diabetic treatment situations.

How to take

Adult dose

The dose of this medication should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of the individual components: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medication is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior history of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, the initial dose is 1 tablet of this medication 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medication 2.5/1000 mg twice daily. 2. Patients who do not achieve adequate glycemic control with metformin monotherapy: The initial dose of this medication should provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medication should start at their current doses of linagliptin and metformin. 4. Patients who do not achieve adequate glycemic control with combination therapy with metformin and a sulfonylurea: The initial dose of this medication should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medication is administered concomitantly with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Administer with caution to the following patients). 5. Patients who do not achieve adequate glycemic control with combination therapy with insulin and metformin: The initial dose of this medication should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medication is administered concomitantly with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Administer with caution to the following patients). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral hypoglycemic agents to this medication. Any change in treatment for type 2 diabetes may cause a change in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, provided the dose is adjusted as follows. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 1. Do not administer to the following patients).

Precautions

This medication may cause a serious side effect called lactic acidosis, so caution is required. It should not be used in patients with allergies to any of the components of this drug or in those with type 1 diabetes, lactic acidosis, or diabetic ketoacidosis. It should not be administered to patients with severely impaired kidney function or in situations where acute changes in kidney function may occur. Furthermore, patients with severe heart disease or liver dysfunction, acute alcohol intoxication, or very poor nutritional status should avoid using this drug. Pregnant or breastfeeding women are also advised not to use this medication. As this drug can cause hypoglycemia, it is essential to monitor blood sugar levels closely, especially when taken with insulin or sulfonylurea. To reduce the risk of lactic acidosis, regular kidney function tests are necessary; this medication should be temporarily discontinued during acute illnesses such as dehydration, severe infections, or trauma. If acute pancreatitis or skin blistering is experienced, immediate consultation with a doctor is required. This medication can lower vitamin B12 levels, therefore checking for vitamin B12 deficiency is necessary during long-term use. When used in conjunction with other drugs, interactions may occur, so it is important to inform the doctor or pharmacist and take caution. For those planning to become pregnant or who are pregnant, insulin therapy is recommended for blood sugar control instead of this drug. Safety in children under 10 years old and adolescents is not established, so it is preferable not to administer it. In elderly patients, there may be a decline in kidney function; hence, dosage adjustments and regular kidney function tests are necessary. In cases of overdose, lactic acidosis may occur and immediate medical attention should be sought; hemodialysis is an effective treatment method. This medication should be kept out of reach of children and stored away from moisture.

Side effects

  • Lactic acidosis
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • vitamin B12 decrease and deficiency
  • hypoglycemia
  • taste disorders
  • cough
  • decreased appetite
Show 108 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • vesicular pemphigoid
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • constipation
  • epigastric pain
  • enterocolitis
  • intestinal obstruction
  • gastroenteritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • speech disorder
  • Alzheimer's dementia
  • chest pain
  • fever
  • facial swelling
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscal injury
  • pneumoconiosis
  • congestive heart failure
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • anxiety
  • mood disorder
  • insomnia
  • depression
  • contusion
  • bone contusion
  • concussion
  • bone fracture
  • laceration
  • palpitations
  • dry eye
  • glaucoma
  • cataract
  • ocular discomfort
  • allergic conjunctivitis
  • polyuria
  • proteinuria
  • stress urinary incontinence
  • hematuria
  • hypotension
  • flushing
  • hepatic steatosis
  • cholelithiasis
  • hearing loss
  • erectile dysfunction
  • thyroid goiter
  • kidney transplant failure
  • anemia
  • dizziness
  • sensory impairment
  • pruritis
  • hypertension
  • benign prostatic hyperplasia
  • stomatitis
  • mediastinitis
  • vitreous hemorrhage
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyp
  • confused state
  • nocturia
  • dermatitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it must be stored in a tightly sealed container. The recommended storage temperature is between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Bright pink, biconvex, oval film-coated tablet

Package unit

60 tablets/box [(10 tablets/PTP packaging x 6)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.